BioAlliance Pharma SA posted record revenue of €15.2 million in the 2010 second quarter in what was an illustration of how the fortunes of a small European company can be transformed by a single regulatory approval in the US.
Boehringer Ingelheim GmbH, reported a 2.8% decline in sales in the first half of 2010, mainly due to generic competition in the US. But it said new product sales would help it achieve a high, single-digit increase in 2011.
The safety and efficacy of the monoclonal antibody, ofatumumab, in the treatment of patients with refractory chronic lymphocytic leukaemia has been demonstrated in a pivotal clinical trial, according to its developers.
Galápagos NV has paid an undisclosed sum to GlaxoSmithKline Plc to re-acquire rights to a candidate drug for rheumatoid arthritis which inhibits a family of enzymes known as Janus kinase (JAK). It will start a Phase 1 study on 9 August.
A new preclinical antibiotic that is being developed by GlaxoSmithKline Plc has been shown in an image fighting bacteria that are resistant to conventional antibiotics.
Novo Nordisk A/S has estimated that sales will grow by 9 to 10% in 2010 based on continued market penetration of its core diabetes products and its new glucagon-like peptide-1 receptor agonist for Type 2 diabetes, Victoza (liraglutide).
GlaxoSmithKline Plc has agreed to pay $23 million upfront for exclusive access to technology developed by Amplimmune Inc of the US for potential therapies for cancer and other diseases. Specifically, GSK will obtain rights to a molecule targeting the membrane protein, PD-1.
Shire Plc expects to increase its spending on research and development this year, even as it prepares to commit €428 million to complete its latest acquisition- an all-cash offer for Movetis NV of Belgium.
Wilex AG has announced the successful completion of a rights issue which has raised €10 million in new money. The proceeds will be used to finance the ongoing clinical development of the company’s oncology portfolio.
With a debt restructuring completed and its core products booking substantial revenue gains in the first half, UCB SA has confirmed its forecast for 2010 revenue of €3 billion and a profit of €700 million.